Fund Allocation - The company plans to allocate a total of HKD 825.6 million from the net proceeds of the global offering, with specific allocations for various purposes[4]. - HKD 222.3 million is designated for product and service innovation, with HKD 149.4 million remaining unutilized as of December 31, 2023[4]. - The company has reallocated HKD 160.0 million from brand enhancement initiatives to operational funds due to a slowdown in expansion and closure of some self-operated clinics[3]. - The actual costs for establishing new hospitals in China were lower than expected, leading to a reallocation of HKD 120.0 million for brand enhancement and operational funds[2]. - The company expects to utilize the remaining funds for operational purposes by December 2025[4]. - The board will continue to evaluate the use of unutilized net proceeds and may adjust plans as market conditions change[5]. Operational Developments - The company has completed the construction of smart hospitals, resulting in a reduction of costs associated with data analysis team development[3]. - As of March 30, 2023, the company has opened a new hospital in Shanghai and transformed existing facilities in Guangzhou and Shenzhen[2]. - The company anticipates a delay in acquiring local non-chain hair transplant institutions over the next year[3]. Strategic Outlook - The board believes that the changes in the use of net proceeds will enhance the company's operational efficiency and profitability[5].
雍禾医疗(02279) - 2024 - 年度业绩